Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
High level of vaccine efficacy maintained over a 6-month period of surveillance
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
In this role, Jeffrey DeAlmeida takes responsibility for BASF’s global pharmaceutical solutions portfolio and the Nutrition & Health business in North and South America
Subscribe To Our Newsletter & Stay Updated
